Ommunal Adulti (Lyophilized Bacterial Lysates Of: Haemophilus Influenzae Streptococcus (Diplococcus) Pneumoniae Kleb)

Ommunal Adulti is employed as an immunostimulant in clinical contexts where enhancement of host defence mechanisms is desired.

• Recurrent respiratory infections: May help reduce the frequency of infections in susceptible adults.
• Post‑operative immune support: Intended to aid recovery of immune function after major surgery.
• Chronic bronchitis exacerbations: Used to support immune defence during flare‑ups.
• Seasonal viral prophylaxis: Administered to bolster immunity during periods of high viral circulation.

• The lyophilized bacterial lysates contain fragmented antigens from Haemophilus influenzae, Streptococcus pneumoniae and Klebsiella species. When introduced, they are processed by antigen‑presenting cells, stimulating both innate and adaptive immune pathways, including activation of macrophages, natural killer cells and T‑lymphocyte responses, thereby enhancing the body’s capacity to recognise and respond to respiratory pathogens.

Adverse reactions reported with bacterial lysate immunostimulants are generally mild and related to the route of administration.

Common Side Effects

• Injection site pain: Discomfort at the site of subcutaneous or intramuscular injection.
• Low‑grade fever: Transient temperature rise within 24 hours.
• Mild headache: Occasional tension‑type headache.
• Fatigue: Temporary feeling of tiredness.
• Local erythema: Redness around the injection area.

Serious or Rare Side Effects

• Anaphylaxis: Severe allergic reaction requiring immediate medical attention.
• Serum sickness‑like reaction: Joint pain, rash and fever occurring days after dosing.
• Severe local necrosis: Tissue damage at the injection site.
• Autoimmune flare: Exacerbation of pre‑existing autoimmune disease.
• Hypotension: Unexplained drop in blood pressure post‑administration.

Before initiating therapy with Ommunal Adulti, clinicians should evaluate patient history and follow standard safety measures.

• Allergy assessment: Confirm no known hypersensitivity to bacterial lysates or any component of the formulation.
• Immunocompromised status: Use with caution in patients with severe immunodeficiency.
• Autoimmune disease: Monitor closely if the patient has active autoimmune conditions.
• Concomitant vaccines: Schedule administration to avoid overlapping immune activation.
• Pregnancy and lactation: Weigh potential benefits against unknown risks; use only if clearly indicated.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ommunal Adulti may interact with other agents that influence immune function. Clinical judgement should guide co‑administration.

Major Interactions (Avoid)

• Live attenuated vaccines: Concurrent use may reduce vaccine efficacy or increase adverse events.
• High‑dose corticosteroids: May blunt the immunostimulatory effect of the lysate.

Moderate Interactions (Monitor Closely)

• Immunomodulatory biologics (e.g., anti‑TNF agents): May alter response to bacterial lysates.
• Antipyretics (acetaminophen, ibuprofen): May mask low‑grade fever, a common post‑dose sign.
• Antihistamines: Could diminish mild injection‑site reactions, affecting safety monitoring.
• Cytokine‑targeting therapies: Potential for synergistic immune activation.
• Hematopoietic growth factors: Overlap in immune‑stimulating pathways warrants observation.